Galderma has announced the launch of a new phase IIb clinical trial that will assess the benefits of a new treatment for atopic dermatitis.
The study will evaluate the effectiveness of nemolizumab, an investigational subcutaneous anti-IL-31 receptor A monoclonal antibody, as a treatment for moderate to severe atopic dermatitis among patients with severe pruritus receiving topical corticosteroids, who have not achieved adequate disease control with topical treatments.
“Galderma has commenced a new clinical study to assess the effectiveness of nemolizumab in the treatment of atopic dermatitis.“
Patients will receive one of three active doses of nemolizumab or placebo administered monthly for six months, with the safety, tolerability and pharmacokinetics of the therapy also set to be assessed.
Dr Thibaud Portal, vice-president of Galderma's prescription business, said: "We hope this trial will confirm the effectiveness and safety of nemolizumab, which will pave the way for confirmatory phase III trials and make nemolizumab a first-in-class solution for atopic dermatitis."
A chronic inflammatory skin disease, atopic dermatitis is the most common form of eczema, and frequently begins in childhood. The condition is characterised by dry, red, and swollen skin and pruritus, leading to a significant impact on sleep and quality of life.
With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Consumer